Laurence Reid - 23 Nov 2024 Form 4 Insider Report for KalVista Pharmaceuticals, Inc. (KALV)

Role
Director
Signature
/s/ Benjamin L. Palleiko, Attorney-in-Fact
Issuer symbol
KALV
Transactions as of
23 Nov 2024
Net transactions value
$0
Form type
4
Filing time
26 Nov 2024, 16:41:52 UTC
Previous filing
25 Sep 2023
Next filing
15 Aug 2025
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KALV Stock Option (Right to Buy) Award $0 +17,000 $0.000000 17,000 23 Nov 2024 Common Stock 17,000 $10.07 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option vests over a 36 month period: 1/36th on December 25, 2024, after which 1/36th of the total shares vest monthly, subject to continued service through each vesting date.